Investigator
Princess Margaret Cancer Centre
Assessment of Homologous Recombination Deficiency in Ovarian Cancer
Summary Accurately assessing homologous recombination deficiency (HRD) to use as a predictive biomarker is an area of intense research in ovarian cancer. Validated assays have demonstrated utility in determining maintenance therapy following platinum sensitive chemotherapy. Novel functional assays promise the potential to reflect HRD in real time and predict response to PARP inhibitors. See related articles by Pikkusaari et al., p. 3110 and Blanc-Durand et al., p. 3124
Precision Endocrine Therapy in Endometrial Cancer: Has Its Time Finally Come?
Summary Endocrine therapy (ET) has been underexplored in endometrial cancer. Emerging data suggest that combining ET with cyclin-dependent kinase 4/6 inhibitors improves outcomes in endometrial cancer. This commentary complements a recent CCR article and reviews the opportunities to improve precision ET and the potential to overcome resistance mechanisms associated with ET failure. See related article by Green et al., p. 2088
IN
